Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2982772 in active ulcerative colitis
NL-OMON45582Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK2982772 in autoimmune colitis (3 arms), sponsored by GSK. Primary endpoint: Adverse effects. Started Jan 2018; status: active, not recruiting.
02
Drugs
GSK2982772
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON45582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45582.